EUVIMEDEUVIMED entdecken
Crossref

ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer

Zhaojuan Liu, Heping Zheng, Yanqing Tian, Zhuoyue Li, Sai Zhang, Siqi Zhang iD, Shumin Ma, Xiao Wang iD, Chong Qin iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Zhaojuan Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Drug Resistance, Neoplasm, Proto-Oncogene Proteins p21(ras), Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Key Technology Research and Development Program of Shandong Province, Qingdao Key Technology Research and Industrialization Demonstration Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer driven by the KRASG12D mutation faces therapeutic challenges from KRAS undruggability and acquired resistance to inhibitors like MRTX1133 via secondary mutations (e.g., Q95/Y96). Here, we report ZJK-807, a novel cereblon (CRBN)-based proteolysis-targeting chimera (PROTAC), conjugating a KRASG12D inhibitor to a CRBN ligand. It selectively degrades KRASG12D (DC50 = 79.5 ± 5.4 nM in AsPC-1 cells) with minimal impact on wild-type KRAS or other mutants (G12C/S/V, G13D), inducing mutant-specific cytotoxicity. Critically, ZJK-807 overcomes secondary mutation resistance by degrading mutant KRASG12D and suppressing resistant cell growth where MRTX1133 fails. Transcriptomic analysis revealed that ZJK-807 suppresses RAS/MAPK signaling and uniquely modulates TNF signaling and eukaryotic ribosome biogenesis, suggesting distinct mechanistic advantages. In vivo, ZJK-807 (30 mg/kg, subcutaneous) achieved 47% tumor growth inhibition in AsPC-1 xenografts with favorable pharmacokinetics. This study presents a CRBN-based PROTAC to selectively target and degrade resistant KRASG12D mutants, establishing a groundbreaking approach for KRAS-driven malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsDrug Resistance, NeoplasmProto-Oncogene Proteins p21(ras)Antineoplastic AgentsHumansAnimalsCell Line, TumorMiceProteolysisMutationCell ProliferationUbiquitin-Protein LigasesXenograft Model Antitumor AssaysAdaptor Proteins, Signal Transducing

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanAntineoplastic AgentsCRBN protein, humanUbiquitin-Protein LigasesAdaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, Shandong 266003, China.
  • Center for Targeted Protein Degradation and Drug Discovery, Ocean University of China, Qingdao, Shandong 266003, China.
  • Marine Biomedical Research Institute of Qingdao, Qingdao, Shandong 266071, China.
  • Laboratory for Marine Drugs and Bioproducts, Qingdao Marine Science and Technology Center, Qingdao, Shandong 266137, China.

ORCID-Profile: Siqi Zhang, Xiao Wang, Chong Qin

Förderung

  • Key Technology Research and Development Program of Shandong Province
  • Qingdao Key Technology Research and Industrialization Demonstration Projects

Zitieren

APA

Liu, Z., Zheng, H., Tian, Y., Li, Z., Zhang, S., Zhang, S., Ma, S., Wang, X., & Qin, C. (2025). ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01034

Vancouver

Liu Z, Zheng H, Tian Y, Li Z, Zhang S, Zhang S, et al. ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01034

BibTeX
@article{Liu2025,
  author = {Liu, Zhaojuan and Zheng, Heping and Tian, Yanqing and Li, Zhuoyue and Zhang, Sai and Zhang, Siqi and Ma, Shumin and Wang, Xiao and Qin, Chong},
  title = {ZJK-807: A Selective PROTAC Degrader of KRASG12D Overcoming Resistance in Pancreatic Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01034}
}
Kostenlos starten →